Belgium’s UCB is acquiring California-based Zogenix, a company focused on rare diseases, in a deal valued up to €1.7 billion ($1.9 billion).
Prellis Biologics entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing the Bay Area biotechnology company’s first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO).
Bayer on January 10 struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen the company’s cell and gene therapy development efforts.
BioSpace reviewed a busy January 5th for collaboration announcements in the life sciences world.
AstraZeneca and Ionis Pharmaceuticals closed out 2021 with the finalization of their collaboration on the development and potential commercialization of eplontersen, an experimental treatment for transthyretin amyloidosis (ATTR).
J&J’s Janssen Pharmaceutical ended a collaboration with San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
Alpine Immune Sciences and Ireland’s Horizon Therapeutics forged a licensing and collaborative research and development agreement valued at up to $1.5 billion to generate up to four preclinical candidates for autoimmune and inflammatory diseases.
Announcements of new AI deals, partnerships and product launches in biopharma are coming at a rapid pace. A new report from Research and Markets, AI In Pharma Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change, predicts this segment will grow from almost $699.3 million in 2020 to more than $2.895 billion in 2025.
Shares of Xencor were down nearly 6 percent after announcing Novartis terminated the company’s rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific, which was part of a 2016 collaboration valued at $2.6 billion.
Prominent life sciences venture capital firm Flagship Pioneering announced a strategic partnership with the Cystic Fibrosis Foundation on November 3.
